On the significance of telomerase activity in human malignant glioma cells

European Journal of Pharmacology

Volumn 407, Issue 1-2, 2000, Pages 27-37

  Vietor, Martin ^a   Winter, Stephen ^a   Groscurth, Peter ^b   Naumann, Ulrike ^a   Weller, Michael ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Chemosensitivity; Glioma; p53; Penclomedine; Telomerase

Indexed keywords

CAMPTOTHECIN; CARMUSTINE; CISPLATIN; CYTARABINE; CYTOTOXIC AGENT; ETOPOSIDE; GEMCITABINE; LOMUSTINE; PENCLOMEDINE; TELOMERASE; TEMOZOLOMIDE; TOPOTECAN; TREOSULFAN;

APOPTOSIS; ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANIMAL; ANTINEOPLASTIC AGENTS; ASTROCYTES; CELL DEATH; CELL SURVIVAL; GENE TRANSFER, HORIZONTAL; GLIOMA; HUMAN; NEOPLASM PROTEINS; PICOLINES; PROTEIN P53; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; SUPPORT, NON-U.S. GOV'T; TELOMERASE; TUMOR CELLS, CULTURED;

EID: 0034722036     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00726-3     Document Type: Article

References (37)

1. Biochemical pharmacology of penclomedine (NSC-338720)
2. Criteria for analyzing interactions between biologically active agents
3. Extension of life-span by introduction of telomerase into normal human cells
4. The association between telomerase, p53, and clinical staging in colorectal cancer
5. Inhibition of telomerase activity by cisplatin in human testicular cancer cells
6. p53 deficiency rescues the adverse effects of telomerase loss and cooperates with telomerase dysfunction to accelerate carcinogenesis
7. Telomerase expression in gliomas including the nonastrocytic tumors
8. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization
9. Differential telomerase expression in human primary intracranial tumors
10. Death ligand/receptor-independent caspase activation mediates drug-induced cell death in malignant glioma cells
11. CD95-mediated apoptosis: no variation in cellular sensitivity during cell cycle progression
12. Telomere loss in cells treated with cisplatin
13. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype
14. Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone
15. Specific association of human telomerase activity with immortal cells and cancer
16. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA
17. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis
18. Antisense telomerase treatment induction of two distinct pathways, apoptosis and differentiation
19. Telomerase activity in human brain tumours
20. Telomerase activity in human gliomas
21. Bcl-2 modulates telomerase activity
22. Telomerase activity of sarcoma cell lines and fibroblasts is independent of p53 status
23. Reduced telomeric signals and increased telomeric associations in human lung cancer cell lines undergoing p53-mediated apoptosis
24. P53 protein exhibits 3'-to-5' exonuclease activity
25. Effect of penclomedine (NSC-338720) on telomere fusions, chromatin blebbing, and cell viability with and without telomerase activity and abrogated p53 function
26. Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2
27. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo
28. Telomerase activity in relation to p53 status and clinico-pathological parameters in breast cancer
29. Differentiation of immortal cells inhibits telomerase activity
30. Chemosensitivity of human malignant glioma: modulation by p53 gene transfer
31. Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing
32. Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells
33. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation
34. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses
35. Betulinic acid-induced apoptosis in glioma cells: a sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing
36. Associations among telomerase activity, p53 protein overexpression, and genetic instability in lung cancer
37. Cell cycle-dependent modulation of telomerase activity in tumor cells